Timothy M. Janetos, MD, Donald J. D’Amico, MD, and Mark J. Gallardo, MD, point to uveitis access, clinical trial rigor, and procedural pharmaceuticals.
Donald J. D'Amico, MD
Advertisement
Donald J. D’Amico, MD, is with Weill Cornell Medicine and New York-Presbyterian Hospital.
Articles by Donald J. D'Amico, MD
Donald J. D’Amico, MD, presents 1-year pivotal results comparing a Wnt pathway agonist with ranibizumab in diabetic macular edema.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
Retinal imaging as a window into atrial fibrillation
2
Comments from the FDA Advisory Committee meeting on SYD-101
3
OT Roundup: 3 FDA approvals, vorolanib insert miss, brepocitinib in uveitis
4
Lambert-Eaton Myasthenic Syndrome: how eye care professionals differentiate it from myasthenia gravis
5